Head-to-head evidence
HS235 vs Sotatercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Activin receptor type IIA (ActRIIA) · full Hypertension pipeline
HS235
Developed by 35Pharma and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Sotatercept · Winrevair
Marketed by Merck & Co. and partners
NCT04896008 · Phase 3 · completed
This trial used real randomization, triple-blinding, a placebo control, and a hard composite clinical endpoint (death, transplant, or hospitalization) in a reasonably sized population (172 participants), a strong design overall. However, the posted results show only descriptive time-to-event estimates (median not reached vs. 9.6 months) without a formal statistical comparison (no hazard ratio or p-value) provided in the record, so whether the primary endpoint was formally met cannot be confirmed from this data alone.
Next expected readout: August 2027 · NCT07356778 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HS235's landscape · Sotatercept's landscape